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Abstract: Total antioxidant status (TAS), and the influence of treatment and correlation between TAS and pa-
rameters involved in metabolic syndrome (MS) in pediatric cancer survivors were evaluated. One hundred chil-
dren and adolescents were studied. Twenty-five survivors received radiotherapy, 12 were obese or overweight.
Additionally, we analyzed TAS in eight children with acute lymphoblastic leukemia (ALL) at diagnosis and
during treatment after remission induction. The control group consisted of 22 healthy children. Serum concen-
trations of TAS, glucose, cholesterol, HDL-cholesterol, triglycerides, fibrinogen and insulin were measured. In
cancer survivors, independently of diagnosis and kind of treatment (radiotherapy anthracyclines administra-
tion), the mean serum TAS did not differ significantly from the control group. No correlations were observed
with age at the time of diagnosis or interval after the end of treatment. TAS values did not correlate with traits of
the metabolic syndrome. In a group of eight patients with ALL at diagnosis and after induction of remission,
TAS values were lower than in the control and cancer survivor groups. Antioxidant status was not found to be
deteriorated in children after anticancer treatment, irrespective of diagnosis or kind of treatment, which might
indicate sufficient antioxidant prevention. However, the possibility of the development of MS and cardiovascu-
lar disease in adulthood indicates the need for future studies. (Folia Histochemica et Cytobiologica 2012, Vol. 50,
No. 3, 468–472)
Key words: cancer survivors, children, antioxidants, metabolic syndrome
Introduction
Oxidative stress, measured as reactive oxygen species
(ROS), plays an important role in cancerogenesis due
to DNA damage and its modification [1]. Anticancer
treatment, radiotherapy and chemotherapy (i.e. cy-
clophosphamide, anthracyclines) induce ROS pro-
duction. This leads to the death of neoplastic cells,
but may also influence damage to healthy cells and
tissues [2–4].
Antioxidant defense is composed of enzymatic (su-
peroxide dismutase — SOD, catalase — CAT, glu-
tathione peroxidase — GTX), and non-enzymatic (vi-
tamin A, vitamin E, vitamin C, thiol antioxidants, al-
bumin, bilirubin, uric acid) antioxidants. Total anti-
oxidant status (TAS) consists of all antioxidants
present in body fluids. At the time of cancer diagno-
sis, and during treatment, the level of antioxidants is
decreased, which can lead to impaired function of
organs such as the heart muscle, lungs or central ner-
vous system [2, 5–7].
The increasing number of childhood cancer survi-
vors has prompted studies into the late effects of an-
ticancer treatment. It is well known that anticancer
therapy damages different organs, not only during
treatment, but also leads to their deteriorated func-
tion many years later. Late cardiotoxicity, lung dam-
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age, and metabolic syndrome are observed in child-
hood cancer survivors. In the development of the se-
quelae, ROS and the antioxidant status play an im-
portant role [3, 4, 8, 9].
Until now, there has been no research into the
relationship between TAS and metabolic syndrome
(MS) in children previously treated for cancer. In the
present study, we evaluated total antioxidant status
in children after anticancer therapy, as well as the
influence of different methods of previously received
treatment, age at the beginning of the therapy, and
correlation with the different traits involved in MS.
Material and methods
Patients. One hundred children and adolescents from the
Outpatient Clinic of the Department of Pediatric Oncology
and Hematology, Medical University of Bialystok, aged from
4.22 to 22.6 years, treated previously for different cancers,
were studied. The patients were scheduled for examination
after at least two years off therapy, as a follow-up study of
cancer survivors. All of them were in the first remissiona
mean of 5.3 ± 2.99 years after the end of treatment. Twen-
ty-five survivors received radiotherapy. In this group,
14 patients had central nervous system irradiation due to
leukemias (dose of 12 or 18 Gy) and 11 were irradiated for
solid tissue sarcomas or Hodgkin’s lymphoma. All children
received normal diet and were in good general condition at
the time of the study. None of the survivors presented overt
or subclinical symptoms of cardiomyopathy, pulmonary dys-
function, hypertension or hormonal dysfunctions. Twelve
patients were obese or overweight (body mass index,
BMI > 85th percentile).
Additionally, we analyzed TAS at diagnosis and after
induction of treatment in eight children diagnosed with ALL
in 2008. All of them received the same protocol for ALL
treatment and were in general good condition at the mea-
surements (infection and acute organ damage to the lungs,
kidneys and heart were excluded). The control group for
TAS evaluation consisted of 22 healthy children with a mean
age of 12.6 ± 4.79 years. Table 1 presents the patients’ char-
acteristics.
Methods. Blood samples were collected after 12 hours of
fasting, centrifuged, and then immediately frozen and stored
at –80°C. The serum concentration of TAS was assayed us-
ing the enzymatic method with peroxidase by commercially
available RANDOX TAS kits (Randox, Ardmore, UK) ac-
cording to the manufacturer’s instructions. In this method,
ABTS® (2,2 Azino-di-[3-ethylbenzthiazoline sulphonate)
is incubated with a peroxidase metmyoglobin and H2O2 to
produce the radical cation ABTS®*+. This product has
a relatively stable blue-green color, which was measured at
600 nm. Antioxidants in the added serum sample cause sup-
pression of this color production to a degree which is pro-
portional to their concentration.
Biochemical tests with automated direct methods (with com-
mercial kits) were used to analyze serum glucose (enzymatic
method with hexokinase, Roche) cholesterol (CHOL) (enzy-
matic method with cholesterol oxidase, Roche), HDL-choles-
terol (HDL) (direct measurement with polyethylene glycol-
modified enzymes, PEG, Roche), triglycerides (TG) (with phos-
phoglycerol oxidase method, Roche), fibrinogen (photo-optical
method, Multifibren U, DADE Behring Diagnostics), insulin
(chemiluminescence immunoassay, Insulin, Immulite Siemens).
Measurements of weight, height, and blood pressure
were obtained using conventional techniques. Body mass
index (BMI) was calculated as weight in kilograms divided
by height in square meters. Abdominal obesity was calcu-
lated from waist-to-hip ratio.
The study was approved by the Ethical Committee of the
Medical University of Bialystok. Written informed consent
was obtained from parents and adolescents (> 16 years).
Statistical analysis was performed using GraphPad Prism
4.0 version. Data was expressed as means ± standard devi-
ations, or when appropriate (depending on skewness) as
median and quartiles. Kruskal–Wallis test was used to ex-
amine differences in continuous variables between patients
in different diagnosis and treatment groups. For compari-
son of nonparametric data sets, Mann–Whitney U test was
used. Spearman’s test was used to assess correlation between
different treatment and time parameters with TAS values.
A p value < 0.05 was considered significant.
Table 1. Patients’ profile in the study group
Characteristics
Gender
Male (n, %) 58 (58%)
Female (n, %) 42 (42%)
Age at study 12.74
(years; median [1st and 3rd quartile]) (8.68; 16.55)
Age at diagnosis (years, mean ± SD) 7.0 ± 4.94
Age at cessation of treatment 8.7 ± 4.89
(years, mean ± SD)
Years since cessation of treatment 5.3 ± 2.99
(mean ± SD)
Diagnosis
Acute lymphoblastic leukemia (n, %) 49 (49%)
Acute non-lymphoblastic leukemia (n, %) 3 (3%)
Non-Hodgkin’s Lymphoma (n, %) 11 (11%)
Hodgkin’s Disease (n, %) 4 (4%)
Solid tumors (n, %) 33 (33%)
Dose of radiotherapy (n, %)
1,200 Gy (central nervous system) 10 (40%)
1,800 Gy (central nervous system) 4 (16%)
> 1,800 Gy (supra- and infradiaphragmatic 11 (44%)
 irradiation)
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The role of ROS in neoplastic transformation and
in the development of different cancers has been con-
firmed by numerous studies in adults and children.
Neoplastic cells produce higher amounts of ROS than
normal cells. The antioxidant system is altered; the
activity of SOD, CAT is reduced and serum vitamin
E is lower, which leads to an imbalance between the
oxidative and antioxidative status [1]. Anticancer
treatment also influences redox status, i.e. some cy-
tostatic agents act by inducing oxidative stress, neo-
plastic cell injury and death [2, 4, 5, 11]. Some au-
thors have suggested that a high level of the apoptot-
ic index can be a marker of good clinical response to
treatment [2]. In childhood leukemia, repeated che-
motherapy protocols contribute to prolonged oxida-
Figure 1. TAS values in children before, during and after
the treatment for pediatric cancer, and in control group
(p value for comparison of four studied groups of patients
p = 0.018; ^comparison of patients before therapy with
control group; *comparison of patients before and after
treatment)
Table 3. Correlation of TAS values and different laboratory
and clinical findings
Feature TAS value p
correlation
BMI 0.15 0.25
Total cholesterol –0.08 0.41
HDL-cholesterol –0.15 0.14
Triglycerides 0.24 0.02
Fibrinogen –0.01 0.89
Fasting glucose 0.18 0.08
Postprandial glucose 0.03 0.81
Fasting insulin 0.22 0.05
Postprandial insulin 0.14 0.27
Results
In the analyzed group of cancer survivors, the
mean serum TAS did not differ significantly from
the values measured in the control group. We
found no differences in TAS after group subdivi-
sion according to diagnosis. No correlations were
observed with age at the time of diagnosis, at the
time of study, or in the time interval between the
end of treatment and this study. There was no ef-
fect of previous treatment, namely use of anthra-
cycline (TAS value in group of patients with an-
thracyclines 1.26 ± 0.214 vs. patients without an-
thracyclines 1.26 ± 0.180; p = 0.91) or radiother-
apy administration (Table 2).
Twelve survivors presented overweight or obe-
sity. We found no differences in TAS values in chil-
dren with normal weight compared to overweight
and obese patients. TAS values did not correlate
with parameters describing the metabolic syn-
drome: BMI, total cholesterol, HDL-CHOL, fibrin-
ogen, fasting and postprandial glucose and insulin,
systolic and diastolic blood pressure. We found
a positive correlation between TAS and triglyce-
ride values (Table 3).
We found no differences in TAS values between
groups of patients with two or more elements of MS
compared to the remaining patients (p = 0.38).
Additionally, we examined TAS in a small group
of eight ALL patients: at diagnosis (before treatment)
and during treatment (after induction chemothera-
py), TAS values were lower than in the control group
and in cancer survivors (Kruskal–Wallis test p = 0.018)
(Figure 1).
Discussion
In our study, normal TAS values were found in all
cancer survivors at a mean 5.3 years after the end of
treatment, irrespective of the type of cancer and the
treatment received. However, in a small group con-
sisting of eight children before and during treatment,
TAS levels were observed to decrease.
Table 2. Correlation between treatment features and TAS
values
Feature TAS value p
correlation
Age at diagnosis 0.03 0.81
Age at time of study 0.02 0.92
Time elapsed since cessation 0.10 0.40
of treatment
Dose of radiotherapy –0.01 0.95
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tive stress, which is associated with the intensity of
treatment [5, 10]. The decreased TAS values observed
in our study before and after intensive treatment in
ALL patients indicate a lack of balance between ele-
vated ROS generation and antioxidant capacity, which
is inefficient. This situation can lead to deteriorated
function of different organs.
Elevated oxidative stress can cause adverse side
effects of treatment, such as cardiotoxicity after an-
thracyclines or hemorrhagic cystitis after cyclophos-
phamide [12, 13]. Anthracyclines generate ROS and
cause myocyte injury. Cardiac myocytes are highly sus-
ceptible to oxidative damage due to their intensive ox-
idative metabolism and relatively poor antioxidant de-
fense [4]. Additionally, mediastinal or lung radiother-
apy influences the generation of ROS, leading to in-
flammation, endothelial injury to the heart muscle, and
to the future development of atherosclerosis and pos-
tradiation fibrosis [2]. Development of postradiation
chronic oxidative stress leads to an imbalance between
ROS and the antioxidant defense, which results in in-
jury to different tissues and organs [3, 9, 14].
The systematic progress in anticancer treatment
in children over the last 40 years has contributed to
an increase in the population of pediatric cancer sur-
vivors. Their health status and quality of life are an
important problem. Second malignancies, cardiovas-
cular and pulmonary sequelae are the commonest
factors influencing late morbidity and mortality of
childhood cancer survivors [8, 15, 16]. Oxidative stress
and antioxidative status are considered important el-
ements in the development of these late effects [3, 4].
Some studies have indicated a favorable influence of
diet with antioxidant supplementation on the reduc-
tion in the toxic effect of ROS-generating chemother-
apies, as well as on a reduced risk of cancer develop-
ment or recurrence [5, 17–19]. There have been few
studies concerning oxidative stress and/or the antiox-
idant status in children during and after anticancer
treatment. All of them were conducted directly after
treatment [7, 10].
In our study group, all cancer survivors were in
the first remission, and none of them presented the
clinical signs of cardiovascular or pulmonary dysfunc-
tion. We did not find decreased TAS values in any of
our survivors, even in those examined a short time
(seven months) after the end of treatment.
Our results indicate that previous radiotherapy and
therapy with anthracyclines had no lasting effect on
the antioxidant status, and even a short time after the
treatment was sufficient for antioxidant status recon-
struction. Similar findings were presented by Battisti
et al., who observed normal CAT and SOD activity in
children and young adults after cessation of leuke-
mia treatment [10].
In our cancer survivors, we assessed a possible cor-
relation between TAS and the traits of metabolic syn-
drome (MS). Truncal obesity, hypertension, hypertrig-
lyceridemia, lowered HDL-cholesterol level, and hy-
perglycemia are the main components of MS. In chil-
dren with full or partial MS, reduced TAS, decreased
levels of plasma antioxidant vitamins and increased
oxidative stress with higher lipid peroxidation are ob-
served. These metabolic alterations lead to endothe-
lial dysfunction and precocious development of ath-
erosclerosis in adulthood [20–24]. In a Dutch analysis,
the MS criteria were observed in 13% of long-term
adult survivors of childhood cancers, especially after
the treatment for brain tumors or acute leukemias with
cranial irradiation [25]. In our study, none of the ana-
lyzed survivors presented all the elements characteris-
tic of MS, yet some of them demonstrated obesity and
hypertriglyceridemia. We found a positive correlation
between TAS and TG levels, but no correlation with
other MS parameters. Twelve survivors were over-
weight, but TAS was not altered in this subgroup. None
of the analyzed patients were hypertensive or demon-
strated glucose metabolism alterations. This indicates
that overweight survivors without other signs of MS
present normal antioxidant capacity. Similar observa-
tions were made by Molnar et al., who noticed reduced
TAS values only in obese children with multimetabolic
syndrome, but in the obese patients without MS the
values of TAS were normal [22]. The mechanism of
MS development in childhood cancer survivors de-
pends on the tumor location (i.e. hypothalamus) and
adverse effect of treatment, i.e. central nervous sys-
tem radiotherapy and/or  subsequent growth hormone
deficiency, thyroid dysfunction, hypogonadism, steroid
therapy [26–28]. In our study group, children irradiat-
ed for central nervous system received a dose of 12 or
18 Gy. These doses influence growth hormone pro-
duction and lead to the development of obesity only to
a small degree [29]. At the time of study, all patients
were euthyreotic, without signs of hypogonadism.
In conclusion, the antioxidant status in children
after anticancer treatment was not found to be dete-
riorated, irrespective of diagnosis or method of treat-
ment, which might indicate sufficient antioxidative
prevention. However, the possibility of MS develop-
ment and cardiovascular disease in adulthood sug-
gests that future studies in this area are necessary.
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